Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in IPF/PF-ILDs
NCT05828953Phase 2Active, not recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) and interstitial lung disease (ILD) comparing Anlotinib with Placebo (2 arms). Primary endpoint: Forced Vital Capacity at 24 weeks. Started Sep 2021; status: active, not recruiting.
02
Drugs
anlotinib
03
Conditions
idiopathic pulmonary fibrosis (IPF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05828953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05828953.